← Insider buys

BJDX

Bluejay Diagnostics, Inc. · Healthcare

Insiders bought $222K of Bluejay Diagnostics, Inc. in the last 12 months

6 insiders bought on 2 days.

$222KBought, 12 mo
$0Sold, 12 mo
$3.3MMarket cap

BJDX over the last year

Insider buy filed (2 days)

Largest buyers, last 12 months

BJDX after insider buys

3 months after each buy, from the first price a copier could get.

−19.0%Average
−9.5 ptsVs S&P 500
0 of 3Higher

3 buys since 2022 with 3 months of prices.

Every filing

8 insider filings since 2022, newest first

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.